Q-omics provides the consensus-scored ETDB profile across patient tissues and cancer cell-line models. ETDB expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ETDB is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, ETDB RNA expression shows 3,755 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight BLCA, LUSC, and KIRC as cancer lineages where ETDB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETDB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETDB survival associations across molecular data types. ETDB RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETDB RNA expression–survival associations across cancer types. High ETDB expression shows unfavorable associations in BLCA, UCEC, COAD and HNSC, but favorable associations in ACC and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for ETDB RNA expression.
This table summarizes ETDB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ETDB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETDB shows lower tumor expression in LUSC. The LUSC box plot shows higher ETDB RNA expression in normal versus tumor tissue (log2 FC = −0.009, t-test p = .046).
This table shows molecular features associated with ETDB in patient tissues and cancer cell lines. In patient samples, ETDB shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, ETDB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
